The Role of Prokaryotic (Probiotic) Produced Megamicro RNAs (memiRNAs) to Prevent or Cure Viral and Nosocomial Infections, Certain Cancers, in Conjunction with Probiotic Induced Eukaryotic Micro RNAs (miRNAs)
Main Article Content
Abstract
In 2021 US Patent # 11,077,052 B1, entitled “Selected Multiphase Treatment for Coronavirus Respiratory Infections” had been issued. The main theme of the successful, practical and novel patent was the use of multiple mixed strain probiotics along with their immunomodulins to prevent or treat Covid-19 infections during the Global Pandemic. The patented invention was accomplished through use of a selective probiotic based Mouth Wash, Nasal Spurge, Nasal Inhalation, and Oral Administration of a Liposomal Preparation. Extensive clinical trials, as outlined in the patent and published data in the peer reviewed journal of Medical Research Archives of the European Society of Medicine titled “ Mechanism of Thrombosis during Covid-19 infection due to SARS-CoV-2 virus and its variants, and a clinically proven strategy to combat with probiotics and their immunomodulins” further proved and validated the invention with regard to its efficacy as a preventative or curative aid to curb Covid-19 infections (after conducting more clinical trials). Logical explanations and partial scientific proof were presented regarding the biochemical mechanism of the multiple mixed strain probiotics and their immunomodulins on curbing Covid-19 infections.
The current investigation was undertaken to study if there could be any other additional factors such as microRNAs, produced by the probiotics as part of the immunomodulins, that might be responsible for the success of this novel patented preventive or treatment modality. Multiple chronological research experiments conducted during this investigation proved that the probiotic-produced intracellular microRNAs, (mega-microRNAs), produced after they attained stationary growth phase, exhibited inhibition of some of the pathogenic bacteria. For the first time in the history of Bacteriology, it was discovered and proven that the autoinhibition of growth of the probiotic bacteria (during stationary phase) was due to the slow down or temporary stoppage of the translation of mRNA coding for the growth proteins by RNA related compounds, preferably miRNAs. The results also proved that probiotics produced microRNAs (mega-microRNAs or memiRNAs) under the influence of bacteriophage exhibited different inhibitory patterns than the ones produced without bacteriophage influence.
Finally, this investigation revealed that the probiotic produced microRNAs have both inhibitory as well as stimulatory effects on bacterial growth protein translation, depending on the conditions and the circumstances under which they were produced. Since they are larger than eukaryotic microRNAs, we have named them, for the first time, as mega-microRNAs or memiRNAs. Thus, miRNA is of eukaryotic origin, whereas memiRNA is of prokaryotic origin. (For the benefit of the reader, these terms have been interchangeably used). The results also proved the partial reason for the success of the invention outlined in US Pat # 11,077,052 B1 to curb RNA viruses could be due to the combined effect of probiotic-produced mega-micro RNAs (memiRNAs) as part of the immunomodulins in conjunction with microRNAs of the host eukaryotic cells, and also the probiotic bacteria themselves.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Smolenski DJ. Micro-RNA - A Nobel winning discovery. Natural Sciences 2024-10-18. https: //.portal.umk.pl/en/article/microrna-a-nobel-winning- discovery#:~:text=In%202024%2C%20the%20Nobel%20Prize,post%2Dtranscriptional%20regulation%20of%20genes
3. Wightman I Ha, Ruvkun. Post transcriptional regulation of the heterochronic gene Lin-14 by Lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993; 75: 855-862.
4. Ruvkun G. “ Glimpses of tiny RNA world. (Perspectives: Molecular Biology) “. Science.2001; 294 (5543), No. 5543: 797.
5. Ambros V, Ruvkun G. Recent molecular genetic explorations of Caenorhabditis elegans MicroRNAs. Genetics. 2018; 209 (3): 651-673. - https://doi.org/10.1534/generics.118.300291.
6. Barrel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009; 136: 215-233.
7. Jason MD, Lund AH. MicroRNA and cancer. Med Oncol. 2012; 6 (6): 439-446.
8. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev enet. 009; 10(10):704.
9. Chen JQ, Papp G, Szodoray P, Zehr M. The role of microRNAs in the pathogenesis of autoimmune diseases. Autoimmun Rev. 2016; 15 (12): 1171-1180.
10. Jinnin M. microRNA in autoimmune disorders. Japanese Journal Of Clinical Immunology. 2011; 34 (6): 439-446.
11. Maes OC, Chertkow HM, Wang E, Schiller HM. MicroRNA: Implications for Alzheimer’s disease and other human CNN disorders. Curr Genomics. 2009; 10(3): 154-168.
12. Chen XM, Huang QC, Yang SL, Chu YL, Yan YH, Han L, et al. Role of Micro RNAs in the pathogenesis of Rheumatoid Arthritis: Novel perspectives based on literature. Medicine. 2015; 94 (31):e 1326.
13. Reddy MS. Mechanism of thrombosis during COVID-19 infection due to SARS-CoV-2 virus and its variants, and a clinically proven strategy to combat with probiotics and their immunomodulins. Medical Research Archives. 2022: 1 – 21. https://esmed.org/MRA/Index.php/mra/article/view/3075
14. Reddy MS. Scientific and medical research on Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy and its influence on assisting to cure or prevent the nosocomial infections, synergistically enhancing the conventional cancer therapies, as an adjuvant, and its possible potential to prevent or cure COVID -19 novel Coronavirus infection by balancing the intestinal Microbiota and Microbiome through modulation of the human immune system. Int J Pharma Sci Nanotech. 2020; 13(3): 4876- 4906. https: //doi.org/10.37285/ijpsn.2020.13.3.3.
15. Reddy MS. Prevention of Viral Transmission by Naked Genetic Material. US Patent # 11,643,641 B2. 2023: 1-20.
16. Reddy MS, Reddy DRK, Prasad NAV. Herbal and pharmaceutical drugs enhanced with probiotics. US Patent # 6, 080, 401. 2000:1-48.
17. Reddy MS, Vedamuthu ER, Washam CJ, ReinboldGW. Differential agar medium for separating Streptococcus lactis and Streptococcus cremoris. Appl Microbiol. 1969; 198: 755-759.
18. Reddy, MS, Vedamuthu ER, Washam CJ, Reinbold GW. Agar medium for differential enumeration of lactic Streptococci. Appl Microbiol. 1972; 24: 947- 952.
19. Reddy MS, Vedamuthu ER, Reinbold GW. A differential broth for separating the lactic streptococci. J Milk Food Technol. 1971; 34: 43-45.
20. Reddy MS, Vedamuthu ER, Washam CJ, Reinbold GW. Associative growth studies in three-strain mixtures of lactic Streptococci. Appl Microbiol. 1972; 25: 953 - 957.
21. Reddy MS, Reddy DRK. Development of multiple mixed strain probiotics for “Probiotic therapy “under clinical conditions, to prevent or cure the deadly hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus aureus (MRSA) Int J Pharma Sci Nanotech. 2016; 9 (3): 3256- 3281.
22. Reddy MS. Probiotics: Genesis, current definition, and proven therapeutic properties. JAAPI. 2021; 1 (2): 18 - 26.
23. Reddy MS. Proven novel method to curtail COVID-19 pandemic, LONG COVID, any further viral pandemics, including influenza due to RNA/DNA viruses, through inactivation of their naked RNA/DNA, and Hospital Acquired [Nosocomial] infections. Arch Neurol & Neuroscience. 2023; 16 (1): 1-20. DOI: 10.33552/ANN 2023. 16. 000880.
24. Reddy MS. Dr. M.S. Reddy’s Multiple Mixed Strain Probiotis Adjuvant Cancer Therapy, to complement immune check point therapy and other traditional cancer therapies, with least autoimmune side effects through eco- balance of human Microbiome. Int J Pharma Sci Nanotech. 2018; 11 (6): 4295- 4317.
25. Reddy MS. Immunomodulatory effect of “ Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy “, to cure or prevent hospital acquired (Nosocomial) infections due to Clostridium difficile (C. diff), other pathogenic bacteria and autoimmune diseases. Int J Pharma Sci Nanotech 2018; 11(1): 3937- 3949.
26. Reddy MS, Reddy DRK. Therapeutic effect of multiple mixed strain probiotics to prevent or cure the hospital associated infections due to Clostridium difficile - C. diff and methicillin resistant Staphylococcus aureus - MRSA. Presented at the 26 th annual AAPI medical convention (American Association of Physicians of Indian origin). June 26-29 (Las Vegas, Nevada, USA), 2008.
27. Reddy MS, Reddy DRK. Isolation and the determination of the major principle or causative agent behind the 2016 published breakthrough discovery of Dr. M. S. Reddy’s “Multiple Mixed Strain Probiotic Therapy “, in successfully treating the lethal hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus aureus (MRSA). Int J Pharma Sci Nanotech. 2016; 9 (6): 3556-3566. https://doi.org/10.37285/ijpsn.2016.9.6.7
28. Reddy MS, Reddy DRK. Therapeutic probiotics for cancer reduction. AAPI journal/ May/ June. 2015: 55-56.
29. Reddy MS, Reddy DRK. Probiotics, biotechnology, and Ayurvedic herbs - complementary and alternative medicine. AAPI Journal / May/ June. 2004: 32-33.
30. Reddy MS, Reddy, DRK. Anti-aging: Review and experimental clinical study of bioavailable calcium - probiotics and their effect on reversing osteopenia, osteoporosis, and other common health conditions. Int J Pharma Sci Nanotech. 2011; 4: 1436 - 1444.
31. Reddy MS. Mechanism of Cytokine Storm in COVID-19: How can probiotics combat it? JAAPI (Journal of the American Physicians of Indian Origin). 2021; 1 (3): 27-35.
32. Voinnet O. Original, biogenesis, and activity of plant microRNAs. Cell. 2009; 136: 669-687.
33. Nogales AR, Algieri F, Garrido-Mesa J, Vezza T, Utrilla MP, Chueca N, et al. The administration of Escherichia coli Nissle 1917 ameliorates development of DSS - induced colitis in mice. Front Pharmacol. 2018; 9: 468.
34. Davoodvandi A, Marzban H, Goleij P, Sahebkar A, Morshedi K, Rezaei S, et al. Effects of therapeutic probiotics on modulation of microRNAs. Cell Communication And Signaling. 2021; 1934: 1-22. https:/doi.org/10.1186/s12964-020-00668-w .
35. Brogna C, Cristoni S, Petrillo M, Bisaccia Dr, Lauritano F, Montano L, et.al. The first report on detecting SARS-CoV-2 inside bacteria of the human gut microbiome: A case series on Asymptomatic family members and a child with Covid-19. F1000 Res. 2024 Oct 16; 11:135. Doi: 10.12688/f1000 research. 77421.3. PMCID: PMC 11502994 PMID: 39464247.